Table 1.
Study design of treatment groups, cyclophosphamide and temsirolimus, monitored with FDG-PET and FLT-PET on d0 (before treatment), d2, d4, d7, d9 and d14. Tumor volumes (Volcalip) were measured with a caliper. Immunohistochemical (IHC) and DNA FACS studies were performed on corresponding days following therapy.
| Cyclophosphamide (n=17) | d0 | d2 | d4 | d7 | d9 | d14 |
|
| ||||||
| FDG-PET + caliper (n=4) | X | X | X | X | X | X |
| FLT-PET + caliper (n=5) | X | X | X | X | X | X |
| IHC and DNA FACS (n=8) † | n=2 | n=2° | n=2 | n=2 | * | |
|
| ||||||
| Temsirolimus (n=17) | d0 | d2 | d4 | d7 | d9 | d14 |
|
| ||||||
| FDG-PET + caliper (n=5) | X | X | X | X | X | X |
| FLT-PET + caliper (n=4) | X | X | X | X | X | X |
| IHC and DNA FACS (n=8) † | n=2 | n=2° | n=2 | n=2 | * | |
|
| ||||||
| Control (n=2) | d0 | |||||
|
| ||||||
| IHC and DNA FACS (n=2) | n=2 | |||||
†
In total 8 mice were sacrificed for analysis on d2,4,7,9 (2 mice per time point);
*
tumors were dissected from mice following their final scan on d14;
°
Only IHC no DNA FACS